Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as...

Prof Bruno Sangro - University of Navarra, Pamplona, Spain

CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )

Novel immunotherapy approaches for small cell lung cancer

Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York City, USA

Novel immunotherapy approaches for small cell lung cancer ( Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York City, USA )

Renal cell cancer: Highlights from ASCO 2020

Prof Scott Tykodi - University of Washington, Seattle, USA

Renal cell cancer: Highlights from ASCO 2020 ( Prof Scott Tykodi - University of Washington, Seattle, USA )

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer ( Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA )

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD...

Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM ( Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA )

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for...

Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion ( Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK )

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal...

Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma ( Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Long-term disease control in multiple myeloma by in-class transitioning: A...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

The future of PARP inhibitors in prostate cancer

Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain

The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

More from ecancer